Compare DRTS & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRTS | OPK |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | Israel | United States |
| Employees | 121 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 978.2M | 1.1B |
| IPO Year | N/A | 2011 |
| Metric | DRTS | OPK |
|---|---|---|
| Price | $12.68 | $1.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.67 | $1.60 |
| AVG Volume (30 Days) | 812.0K | ★ 2.9M |
| Earning Date | 05-18-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $699.98 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $0.98 |
| 52 Week High | $14.11 | $1.61 |
| Indicator | DRTS | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 38.88 |
| Support Level | $6.59 | $1.25 |
| Resistance Level | N/A | $1.41 |
| Average True Range (ATR) | 0.86 | 0.07 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 70.26 | 0.00 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.